Follow
Sabina Antoniu
Sabina Antoniu
Verified email at umfiasi.ro
Title
Cited by
Cited by
Year
Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.
SA Antoniu
Current opinion in investigational drugs (London, England: 2000) 11 (11 …, 2010
832010
Targeting RhoA/ROCK pathway in pulmonary arterial hypertension
SA Antoniu
Expert opinion on therapeutic targets 16 (4), 355-363, 2012
702012
New therapeutic options in the management of COPD–focus on roflumilast
SA Antoniu
International journal of chronic obstructive pulmonary disease 6, 147, 2011
552011
Targeting the TNF-α pathway in sarcoidosis
SA Antoniu
Expert opinion on therapeutic targets 14 (1), 21-29, 2010
542010
Inhaled colistin for lower respiratory tract infections
SA Antoniu, I Cojocaru
Expert opinion on drug delivery 9 (3), 333-342, 2012
512012
Pirfenidone for the treatment of idiopathic pulmonary fibrosis
SA Antoniu
Expert opinion on investigational drugs 15 (7), 823-828, 2006
442006
Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study
SA Antoniu, E Petrescu, R Stanescu, E Anisie, L Boiculese
Therapeutic advances in respiratory disease 10 (1), 26-33, 2016
422016
Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic …
SA Antoniu
Expert Opinion on Therapeutic Targets 15 (3), 351-353, 2011
422011
MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma.
SA Antoniu
Current opinion in molecular therapeutics 12 (2), 233-239, 2010
402010
Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
SA Antoniu, MR Kolb
IDrugs: the investigational drugs journal 13 (5), 332-345, 2010
392010
Measuring fatigue as a symptom in COPD: from descriptors and questionnaires to the importance of the problem
SA Antoniu, D Ungureanu
Chronic Respiratory Disease 12 (3), 179-188, 2015
382015
Targeting PDGF pathway in pulmonary arterial hypertension
SA Antoniu
Expert opinion on therapeutic targets 16 (11), 1055-1063, 2012
372012
Pharmacotherapy of cough-variant asthma
SA Antoniu, T Mihaescu, CF Donner
Expert opinion on pharmacotherapy 8 (17), 3021-3028, 2007
372007
Descriptors of dyspnea in obstructive lung diseases
SA Antoniu
Multidisciplinary respiratory medicine 5 (3), 1-4, 2010
312010
Anti-TNF-α therapies in chronic obstructive pulmonary diseases
SA Antoniu, F Mihaltan, R Ulmeanu
Expert opinion on investigational drugs 17 (8), 1203-1211, 2008
312008
Predictors of mortality in patients with COPD and chronic respiratory failure: the quality-of-life evaluation and survival study (QuESS): a three-year study
M Carone, S Antoniu, P Baiardi, VS Digilio, PW Jones, G Bertolotti, ...
COPD: Journal of Chronic Obstructive Pulmonary Disease 13 (2), 130-138, 2016
272016
Adherence to inhaled therapy in COPD: effects on survival and exacerbations
SA Antoniu
Expert Review of Pharmacoeconomics & Outcomes Research 10 (2), 115-117, 2010
272010
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
SA Antoniu
Multidisciplinary respiratory medicine 7 (1), 1-4, 2012
252012
Mogamulizumab, a humanized mAb against CC chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.
SA Antoniu
Current opinion in molecular therapeutics 12 (6), 770-779, 2010
252010
Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa
S Antonela Antoniu
Expert Review of Anti-infective Therapy 10 (12), 1439-1446, 2012
232012
The system can't perform the operation now. Try again later.
Articles 1–20